Gilead Sciences has been treading water for the past six months, holding steady at $112.78. The stock also fell short of the S&P 500’s 16.5% gain during that period.
The U.S. economy finds itself at a critical juncture, as signals from The Conference Board's Leading Economic Index (LEI) point toward a sustained period of economic weakening. While the LEI's consistent downward trend has historically preceded recessions, The Conference Board maintains a nuanced outlook, forecasting a "significant slowdown" rather
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Monday. Stay informed about the latest market trends.
Gilead Sciences (GILD) is a strong value investing candidate, trading at a significant discount with high profitability, solid financial health, and positive growth prospects.
The American economy is facing a new headwind as weakening wage growth begins to temper consumer spending, raising concerns about the pace and sustainability of the broader economic recovery. Recent data indicates a moderation in the rate at which workers' earnings are increasing, a trend that, while potentially helping to
American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products, and even the cost of staying healthy, prices are already on an upward trajectory or are poised for substantial hikes.
On Monday, the tech-heavy Nasdaq Composite climbed to a new high despite the ongoing uncertainty regarding the state of the U.S. economy and the rate outlook.
The global economy is currently grappling with a projected deceleration in GDP growth, a situation severely exacerbated by an unprecedented escalation of U.S. tariffs. These twin forces are creating a potent cocktail of stagflationary pressures, threatening to disrupt corporate supply chains, erode investor confidence, and reshape the landscape of
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 9.7%.
Markets dipped Thursday as Coty issued a dismal forecast, Gilead faced headwinds with its new HIV drug, and investors turned cautious ahead of Fed Chair Powell’s Jackson Hole speech. Solid PMI data complicated the interest rate outlook, stalling hopes for imminent rate cuts.
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD)
fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to its commercial insurance plans for now.
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.
